|
Disclaimer: FOR TEST AND EXAMPLE PURPOSES ONLY! These web pages are not intended to be used as a source of information on medicines.
The web pages are not kept up to date and are for demonstration purposes only.
For up-to-date information on a medicine, please consult www.ema.europa.eu/medicines or the package leaflet of your medicine.
|
BACK TO LIST |
|
|
|
|||||||||||||||||||||||||
| Test | 23-MAY-2020 | Reference Range | Unit |
|---|---|---|---|
| Leukocytes [#/volume] in Blood by Automated count | 6.0 | 4 - 11 | 10*3/uL |
| Erythrocytes [#/volume] in Blood by Automated count | 5.1 | 3.8 - 5.7 | 10*6/uL |
| Hemoglobin [Mass/volume] in Blood | 15.7 | 12 - 16 | g/dL |
| Hematocrit [Volume Fraction] of Blood by Automated count | 44.3 | 38 - 56 | % |
| MCV [Entitic volume] by Automated count | 87.6 | 78 - 98 | fL |
| MCH [Entitic mass] by Automated count | 31.7 | 27 - 34 | pg |
| MCHC [Mass/volume] by Automated count | 35.2 H | 32 - 35 | g/dL |
| Erythrocyte distribution width [Entitic volume] by Automated count | 39.8 | 36 - 55 | fL |
| Platelets [#/volume] in Blood by Automated count | 435.2 H | 157 - 415 | 10*3/uL |
| Platelet distribution width [Entitic volume] in Blood by Automated count | 245.0 H | 13.4 - 17.4 | fL |
| Platelet mean volume [Entitic volume] in Blood by Automated count | 9.6 | 7.4 - 12 | fL |
| Test | 23-MAY-2020 | Reference Range | Unit |
|---|---|---|---|
| Cholesterol [Mass/volume] in Serum or Plasma | 268.3 H | 130 - 200 | mg/dL |
| Triglyceride [Mass/volume] in Serum or Plasma | 141.6 | 0 - 199 | mg/dL |
| Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay | 185.2 H | 0 - 130 | mg/dL |
| Cholesterol in HDL [Mass/volume] in Serum or Plasma | 54.8 | 50 - 100 | mg/dL |
| Conclusion and Recommendations based on this report and previous findings known to us |
|---|
| The patient shows elevated total and LDL cholesterol, indicating increased cardiovascular risk. Platelet count and platelet distribution width are also elevated, which may suggest reactive thrombocytosis or underlying inflammation but should be correlated clinically. Other hematological parameters are within normal limits. Lipid management and further evaluation of platelet abnormalities are recommended. |